Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Epidemiology of metabolic dysfunction-associated steatotic liver disease

Zobair M. Younossi, Markos Kalligeros, Linda Henry

Clin Mol Hepatol. 2025;31(Suppl):S32-S50. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0431

View: 9954 Download: 1,755 Crossref: 35

Original Article

Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea

Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong

Clin Mol Hepatol. 2023;29(2):496-509. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2022.0345 Correction in: Clin Mol Hepatol 2023;29(3):830

View: 4873 Download: 170 Web of Science: 2 Crossref: 2

Correspondence

Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2023;29(1):185-187. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0375

View: 3502 Download: 49

Letter to the Editor

Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”

Hye Won Lee

Clin Mol Hepatol. 2023;29(1):169-170. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0384

View: 3807 Download: 58 Web of Science: 1 Crossref: 1

Review

Development and prognosis of hepatocellular carcinoma in patients with diabetes

Takuma Nakatsuka, Ryosuke Tateishi

Clin Mol Hepatol. 2023;29(1):51-64. Published online July 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0095

View: 7015 Download: 267 Web of Science: 32 Crossref: 34

Original Article

The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2022;28(4):814-826. Published online June 9, 2022

DOI: https://doi.org/10.3350/cmh.2022.0099

View: 6155 Download: 214 Web of Science: 23 Crossref: 25

Editorial

Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2022;28(4):802-805. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0249

View: 3828 Download: 88 Web of Science: 4 Crossref: 5

Original Article

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial

Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Jin Mo Yang, Kyun-Hwan Kim, Kwang-Hyub Han, Soon Ho Um

Clin Mol Hepatol. 2021;27(2):346-359. Published online January 25, 2021

DOI: https://doi.org/10.3350/cmh.2020.0307

View: 7005 Download: 264 Web of Science: 12 Crossref: 10

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn

Clin Mol Hepatol. 2020;26(3):352-363. Published online May 28, 2020

DOI: https://doi.org/10.3350/cmh.2019.0044n

View: 5960 Download: 200 Web of Science: 6 Crossref: 9

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti

Clin Mol Hepatol. 2020;26(1):45-53. Published online September 30, 2019

DOI: https://doi.org/10.3350/cmh.2019.0031

View: 9216 Download: 272 Web of Science: 23 Crossref: 17

Review

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti

Clin Mol Hepatol. 2019;25(1):30-36. Published online January 23, 2019

DOI: https://doi.org/10.3350/cmh.2018.0061

View: 8681 Download: 158 Web of Science: 16 Crossref: 18

Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL

Jong Eun Yeon

Clin Mol Hepatol. 2018;24(3):278-293. Published online May 2, 2018

DOI: https://doi.org/10.3350/cmh.2018.1002

View: 11480 Download: 244 Web of Science: 15 Crossref: 14

Original Article

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience

Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim

Clin Mol Hepatol. 2017;23(4):323-330. Published online September 5, 2017

DOI: https://doi.org/10.3350/cmh.2017.0005

View: 8349 Download: 183 Web of Science: 8 Crossref: 11

Editorial

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?

Joon Yeul Nam, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(4):311-313. Published online December 4, 2017

DOI: https://doi.org/10.3350/cmh.2017.0069

View: 6790 Download: 148

Original Article

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir

Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin

Clin Mol Hepatol. 2017;23(3):230-238. Published online June 30, 2017

DOI: https://doi.org/10.3350/cmh.2017.0003

View: 10484 Download: 168 Web of Science: 12 Crossref: 15

Editorial

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?

Yun Bin Lee, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(3):219-221. Published online September 19, 2017

DOI: https://doi.org/10.3350/cmh.2017.0045

View: 8461 Download: 155 Web of Science: 1 Crossref: 2

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Byung-Cheol Song

Clin Mol Hepatol. 2016;22(4):439-442. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0108

View: 8401 Download: 113 Web of Science: 1 Crossref: 1

Original Article

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy

Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon

Clin Mol Hepatol. 2016;22(2):241-249. Published online June 15, 2016

DOI: https://doi.org/10.3350/cmh.2015.0053

View: 10662 Download: 141 Web of Science: 4 Crossref: 4

Editorial

Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?

Hyung Joon Yim

Clin Mol Hepatol. 2016;22(2):238-240. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0103

View: 9071 Download: 99 Web of Science: 1 Crossref: 1

Original Article

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B

Chan Ho Park, Seok Won Jung, Jung Woo Shin, Mi Ae Bae, Yoon Im Lee, Yong Tae Park, Hwa Sik Chung, Neung Hwa Park

Clin Mol Hepatol. 2016;22(1):152-159. Published online March 28, 2016

DOI: https://doi.org/10.3350/cmh.2016.22.1.152

View: 10184 Download: 97

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy

Jung Gil Park, Soo Young Park

Clin Mol Hepatol. 2015;21(3):242-248. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.242

View: 8994 Download: 88 Web of Science: 5 Crossref: 4

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients

Joo An Hwang, Kee Bum Kim, Min Jae Yang, Sun Gyo Lim, Jae Chul Hwang, Jae Youn Cheong, Sung Won Cho, Soon Sun Kim

Clin Mol Hepatol. 2015;21(2):131-140. Published online June 26, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.2.131

View: 8937 Download: 87 Web of Science: 2 Crossref: 2

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B

Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol. 2014;20(3):274-282. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.274

View: 7476 Download: 48 Web of Science: 3 Crossref: 2

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir

EunYoung Ze, Eun Kyung Baek, Jong Jin Lee, Han Wook Chung, Dae Geon Ahn, Hwan Jun Cho, Jae Cheol Kwon, Hyung Joon Kim, HyunWoong Lee

Clin Mol Hepatol. 2014;20(3):267-273. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.267

View: 8720 Download: 77 Web of Science: 4 Crossref: 5

The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients

Hee Jae Jung, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Boo Sung Kim

Clin Mol Hepatol. 2014;20(1):38-46. Published online March 26, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.1.38

View: 9692 Download: 86 Web of Science: 32 Crossref: 31

HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data

Jeong Han Kim, Yun Jung Choi, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol. 2013;19(4):409-416. Published online December 28, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.4.409

View: 7077 Download: 64 Crossref: 6

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B

Sang Hoon Ahn, Ji-Yong Chun, Soo-Kyung Shin, Jun Yong Park, Wangdon Yoo, Sun Pyo Hong, Soo-Ok Kim, Kwang-Hyub Han

Clin Mol Hepatol. 2013;19(4):399-408. Published online December 28, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.4.399

View: 7774 Download: 54 Crossref: 2

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients

Jeong Han Kim, Soon Young Ko, Won Hyeok Choe, So Young Kwon, Chang Hong Lee

Clin Mol Hepatol. 2013;19(3):273-279. Published online September 30, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.3.273

View: 8150 Download: 44 Crossref: 1

Review

Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade

Hyung Joon Yim, Seong Gyu Hwang

Clin Mol Hepatol. 2013;19(3):195-209. Published online September 30, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.3.195

View: 12511 Download: 74 Crossref: 24

Original Article

The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults

Deok Yun Ju, Young Gil Choe, Yong Kyun Cho, Dong Suk Shin, Su Hyeon Yoo, Seo Hyoung Yim, Ji Yong Lee, Jung Ho Park, Hong Joo Kim, Dong Il Park, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim

Clin Mol Hepatol. 2013;19(2):140-147. Published online June 27, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.2.140

View: 9051 Download: 77 Crossref: 27

1 | 2 |

Viewed By 8319	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7304	MAFLD: How is it different from NAFLD?
Viewed By 5286	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4944	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4519	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 319	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 291	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search